image header

Investor Overview

Investor Overview

We are a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Our lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept is currently in multiple Phase 1 and 2 clinical trials and has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors. Our strategy is to pursue evorpacept as a potentially critical component of future oncology combination treatments.

ALX Oncology

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

Nov 13, 2023

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update Read more

Nov 1, 2023

ALX Oncology Announces November Investor Conference Participation Read more

Oct 10, 2023

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Read more

Upcoming Events
There are no upcoming events scheduled at this time.